Cargando…

Durvalumab-induced thyroiditis in a patient with non-small cell lung carcinoma: a case report and review of pathogenic mechanisms

BACKGROUND: Immune checkpoint inhibitors (ICI) targeting cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), programmed cell death protein 1 and its ligand (PD-1/PD-L1) have become the current standard-of-care for advanced cancers. This novel therapeutic approach comes with its costs in the form o...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Filette, Jeroen M. K., André, Stéphanie, De Mey, Lynn, Aspeslagh, Sandrine, Karmali, Rafik, Van der Auwera, Bart J, Bravenboer, Bert
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682778/ https://www.ncbi.nlm.nih.gov/pubmed/36419114 http://dx.doi.org/10.1186/s12902-022-01190-5

Ejemplares similares

Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review
por: de Filette, Jeroen M K, et al.
Publicado: (2019)

Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab
por: de Filette, Jeroen, et al.
Publicado: (2016)

COVID-19 and Cushing’s disease in a patient with ACTH-secreting pituitary carcinoma
por: de Filette, J M K, et al.
Publicado: (2022)

SUN-923 Combination Immune Checkpoint Inhibitor Therapy for ACTH-Secreting Pituitary Carcinoma
por: de Filette, Jeroen M K, et al.
Publicado: (2020)

Immune checkpoint inhibitor therapy for ACTH-secreting pituitary carcinoma: a new emerging treatment?
por: Sol, Bastiaan, et al.
Publicado: (2020)

Durvalumab for urothelial carcinoma, non-small cell lung cancer
Publicado: (2019)

Update on Targeted Therapies for Advanced Non-Small Cell Lung Cancer: Durvalumab in Context
por: Gullapalli, Sneha, et al.
Publicado: (2020)

Paraneoplastic myelitis associated with durvalumab treatment for extensive-stage small cell lung cancer
por: Wang, Lan, et al.
Publicado: (2021)

Case Report: Durvalumab-Associated Encephalitis in Extensive-Stage Small Cell Lung Carcinoma
por: Shionoya, Yosuke, et al.
Publicado: (2021)

Durvalumab for Extensive-Stage of Small-Cell Lung Cancer With Lambert-Eaton Myasthenic Syndrome
por: Machiyama, Hirotomo, et al.
Publicado: (2023)

Case Report: Limbic encephalitis following treatment with durvalumab for small-cell lung cancer
por: Moss, Thomas T., et al.
Publicado: (2023)

Durvalumab activity in previously treated patients who stopped durvalumab without disease progression
por: Sheth, Siddharth, et al.
Publicado: (2020)

Simultaneous onset of type 1 diabetes mellitus and silent thyroiditis under durvalumab treatment
por: León Mengíbar, Jose, et al.
Publicado: (2019)

Durvalumab: First Global Approval
por: Syed, Yahiya Y.
Publicado: (2017)

Retinal Vasculitis Secondary to Durvalumab
por: R. Andrade, Antonio, et al.
Publicado: (2020)

Durvalumab-induced Severe Gastritis
por: Otohara, Masaya, et al.
Publicado: (2021)

Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer
por: Shafique, Michael R, et al.
Publicado: (2018)

Durvalumab-induced Immune-related Hepatitis in a Patient with Non-small Cell Lung Cancer
por: Nakamura, Masakatsu, et al.
Publicado: (2020)

Asthma caused by durvalumab after chemoradiotherapy in two patients with non‐small cell lung cancer
por: Uemura, Takehiro, et al.
Publicado: (2021)

Implications of pneumonitis after chemoradiation and durvalumab for locally advanced non-small cell lung cancer
por: Hassanzadeh, Comron, et al.
Publicado: (2020)

Steroid-dependent pericarditis following anti-PD1 immunotherapy in a metastatic melanoma patient: a case report
por: Verhaert, Marthe, et al.
Publicado: (2023)

Identification of characteristics predictive of long-term survival with durvalumab or durvalumab plus tremelimumab in metastatic urothelial carcinoma
por: Alt, Marie, et al.
Publicado: (2023)

Coronavirus disease 2019–related Kawasaki-like disease in an adult: A case report
por: Chérif, Mohammad Yassine, et al.
Publicado: (2020)

Cost‐effectiveness analysis of the new oncological drug durvalumab in Italian patients with stage III non‐small cell lung cancer
por: Buja, Alessandra, et al.
Publicado: (2022)

Myositis induced by durvalumab in a patient with non‐small cell lung cancer: A case report
por: Kobayashi, Miyuki, et al.
Publicado: (2020)

Durvalumab plus novel agents in non-small cell lung cancer—a new COAST on the horizon?
por: Dempke, Wolfram C. M., et al.
Publicado: (2022)

Effects of combination treatment with durvalumab plus tremelimumab on the tumor microenvironment in non-small-cell lung carcinoma
por: Cheng, Li, et al.
Publicado: (2021)

Use of durvalumab in stage III non‐small‐cell lung cancer based on eligibility for the PACIFIC study
por: Boys, Emma, et al.
Publicado: (2023)

Exploring causes and consequences of early discontinuation of durvalumab after chemoradiotherapy for non-small cell lung cancer
por: Pennock, Michael, et al.
Publicado: (2023)

Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung Cancer
por: Preti, Beatrice T. B., et al.
Publicado: (2023)

Onychopathy Following Durvalumab Treatment for Extensive-Stage Small-Cell Lung Cancer: A Case Report
por: Zhang, Cuifen, et al.
Publicado: (2023)

Minimal Change Disease Associated With Durvalumab
por: Toda, Masataro G., et al.
Publicado: (2021)

SAT-506 Rare Case of Durvalumab-Induced Thyroiditis, Transient Secondary Adrenal Insufficiency and Autoimmune Diabetes
por: Gorantla, Yamuna, et al.
Publicado: (2020)

Predictors of Pneumonitis in Patients With Locally Advanced Non-Small Cell Lung Cancer Treated With Definitive Chemoradiation Followed by Consolidative Durvalumab
por: Diamond, Brett H., et al.
Publicado: (2022)

Durvalumab for stage III non-small-cell lung cancer patients: clinical evidence and real-world experience
por: Botticella, Angela, et al.
Publicado: (2019)

Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non‐small cell lung cancer: Management of adverse events
por: Miura, Yu, et al.
Publicado: (2020)

Durvalumab after concurrent chemotherapy and high-dose radiotherapy for locally advanced non-small cell lung cancer
por: Landman, Yosef, et al.
Publicado: (2021)

Prognostic impact of pneumonitis after durvalumab therapy in patients with locally advanced non-small cell lung cancer
por: Nishimura, Ari, et al.
Publicado: (2021)

Multi-institutional analysis of aneuploidy and outcomes to chemoradiation and durvalumab in stage III non-small cell lung cancer
por: Alessi, Joao V, et al.
Publicado: (2023)

Acute Heart Failure as a First Presentation of Pheochromocytoma Complicated with “Inverted” Takotsubo Syndrome
por: Spapen, Jerrold, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_sbrdu1ahuoafg9tgv9lk0cc0qa